Potentiation of Anti-Tumor Efficacy Resulting from the Combined Administration of Interferon α and of an Anti-Breast Epithelial Monoclonal Antibody in the Treatment of Breasl Cancer Xenografts
It has been previously shown that natural interferons(nIFNS) and-α and -γ delivered intralesionally(IL) to xenografts of human breast carcinomas in nude mice exerted a greater inhibitory effect than when they were administered systemically(1). Similarly, in patients with advanced malignant melanoma treated with IL injections of IFNα the local anti-tumoreffects were found to be significantly greater than the systemic effects(2). These observations suggest that the success of IFN therapy may depend, at least in part, on the ability to concentrate the IFN in the target tissue. Unfortunately, to achieve high local concentrations of IFN without causing undesirable side effects is difficult because IFNs are rapidly eliminated. Therefore, it would be desirable to devise means by which IFNs could be selectively delivered to tumors and retained in them for long periods of ti me. This might be possible by coupling IFNs to monoclonal antibodies(MoAbs) directed against antigens specifically expressed by the tumor cells.
KeywordsHuman Breast Carcinoma Advanced Malignant Melanoma Human Breast Cancer Xenograft Human Leukocyte Interferon Human Mammary Carcinoma Cell
Unable to display preview. Download preview PDF.
- 13.L. Ozzello, D.V. Habif, C.M. DeRosa, and K. Cantell, Effects of intralesional injections of interferons α on xenografts of human mammary carcinomacells(BT 20 and MCF-7), J. Interferon Res. 8:208(1988).Google Scholar